Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123543 | 0.92 | MAPT (0.42) | MAPTHTTNPSR1LMNAKDM4E | |
| SCHEMBL6858630 | 0.92 | MAPT (0.42) | MAPTHTTNPSR1LMNAKDM4E | |
| SCHEMBL7127522 | 0.90 | MAPT (0.49) | MAPTHTTNPSR1LMNAKDM4E | |
| SCHEMBL7116814 | 0.89 | MAPT (0.42) | MAPTHTTNPSR1LMNAKDM4E | |
| SCHEMBL6853088 | 0.87 | MAPT (0.44) | MAPTHTTNPSR1LMNAKDM4E | |
| SCHEMBL6853300 | 0.87 | ALDH1A1 (0.46) | MAPTHTTNPSR1LMNAKDM4E | |
| SCHEMBL6314892 | 0.86 | SLC9A1 (0.42) | MAPTHTTNPSR1LMNAKDM4E | |
| SCHEMBL6316509 | 0.84 | SLC9A1 (0.42) | MAPTHTTNPSR1LMNAKDM4E | |
| SCHEMBL7127033 | 0.83 | MAPT (0.46) | MAPTHTTNPSR1LMNAKDM4E | |
| SCHEMBL7115887 | 0.83 | TUBB1 (0.51) | MAPTHTTNPSR1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453783-A1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | Aventis Pharma S.A. (FR) | 2004-09-08 | — | — | EP | disclosed |
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2003-08-07 | — | — | US | disclosed |
| WO-2003048096-A1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | AVENTIS PHARMA S.A. (FR) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | ABL1, MCL1, AHR | MAPT 4538/4885HTT 2064/4885NPSR1 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.